| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 01/15/2003 | CN1098849C 噻唑衍生物 Thiazole derivatives |
| 01/14/2003 | US6506874 Hypoglycemic agents; obesity, nervous system, cardiovascular, and kidney disorder treatment |
| 01/14/2003 | US6506799 Treating or preventing a cardiovascular disease in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of 6-(6-hydroxy-5,5-dimethylhexyloxy)-2,2-dimethyl-hexan-1-ol and |
| 01/14/2003 | US6506779 Acetylene derivatives as anti-inflammatory/analgesic agents |
| 01/14/2003 | US6506775 Substituted benzylaminopiperidine compounds |
| 01/14/2003 | US6506774 The use of orexin receptor antagonists as neuroprotectants, and in the treatment of nausea and vomiting, irritable bowel syndrome and other conditions associated with visceral pain. |
| 01/14/2003 | US6506762 Certain alkylene diamine-substituted heterocycles |
| 01/14/2003 | US6506750 Morpholine derivatives, method for the production thereof and pharmaceutical preparations containing said derivatives |
| 01/14/2003 | US6506741 Remedies for glomerulosclerosis |
| 01/14/2003 | US6506740 Compounds that can be substituted at the 7, 8, and/or 9 positions and methods for preparing the 4- dedimethylamino tetracycline compounds. Other tetracycline compounds are the 4-dedimethylaminotetracycline derivatives with an oxime |
| 01/14/2003 | US6506411 Anti-angiogenic compositions and methods of use |
| 01/14/2003 | CA2065270C Erection-inducing methods and compositions |
| 01/13/2003 | WO2002006237A1 Medicine comprising dicyanopyridine derivative |
| 01/13/2003 | CA2415899A1 Medicine comprising dicyanopyridine derivative |
| 01/09/2003 | WO2003003004A2 Method for identifying compounds the specifically deplete mast cells |
| 01/09/2003 | WO2003002561A1 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 01/09/2003 | WO2003002555A1 Methods of using soluble epoxide hydrolase inhibitors |
| 01/09/2003 | WO2003002553A2 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | WO2003002544A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 01/09/2003 | WO2003002531A2 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | WO2003002530A2 Pyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | WO2003002147A1 Preventives/remedies for organ functional disorders and organ dysfunction |
| 01/09/2003 | WO2003002140A1 Use of poly-glu, tyr and t cells treated therewith for neuroprotection therapy |
| 01/09/2003 | WO2003002130A1 Fat-binding polymers |
| 01/09/2003 | WO2003002124A1 USE OF BIS-ACID(5-ANDROSTEN-17-ONE-3β-HYDROXYL) DIESTERS FOR MANUFACTURE PHARMACEUTICALS |
| 01/09/2003 | WO2003002118A1 Substituted 8-arylquinoline pde4 inhibitors |
| 01/09/2003 | WO2003002109A2 Use of tyrosine kinase inhibitors for treating autoimmune diseases |
| 01/09/2003 | WO2003002092A2 Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same |
| 01/09/2003 | WO2003002088A2 Use of an oil of the gourd family for inhibiting 5$g(a)-reductase activity |
| 01/09/2003 | WO2002081020A3 Method for preventing acute renal failure |
| 01/09/2003 | WO2002072536A8 Urea derivatives having vanilloid receptor (vr1) antagonist activity |
| 01/09/2003 | WO2002071874A3 Composition improving age-related physiological deficits and increasing longevity |
| 01/09/2003 | WO2002062777A9 Amino ceramide-like compounds and therapeutic methods of use |
| 01/09/2003 | WO2002059111A3 Pyrazole compounds useful as protein kinase inhibitors |
| 01/09/2003 | WO2002051443A3 Aqueous gel comprising a gelling agent such as kappa carrageenan and at least 85 % water |
| 01/09/2003 | WO2002046373A9 Method of collecting placental stem cells |
| 01/09/2003 | WO2002014485A3 Kallikrein gene |
| 01/09/2003 | WO2002009716A3 Use of an aldehyde 5-oxo-1,2,4-triazine hydrazide for the treatment of cancer |
| 01/09/2003 | WO2002000017A3 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of erk-5 |
| 01/09/2003 | WO2001079480A9 Albumin fusion proteins |
| 01/09/2003 | WO2001072728B1 Novel piperazine derivatives |
| 01/09/2003 | US20030008915 Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents |
| 01/09/2003 | US20030008909 For therapy of uterine myometrial fibroids, endometriosis, benign prostatic hypertrophy; carcinomas and adenocarcinomas of endometrium, ovary, breast, colon, prostate, pituitary, meningioma and other hormone-dependent tumors |
| 01/09/2003 | US20030008906 Administering benzothiazole compound for therapy, prophylaxis of disease |
| 01/09/2003 | US20030008899 For use as medicine for antagonising the effects of excitatory amino acids upon the NMDA receptor complex |
| 01/09/2003 | US20030008893 For prophylaxis and therapy of diseases associated with monocyte accumulation, lymphocyte accumulation or leucocyte accumulation |
| 01/09/2003 | US20030008889 Aminoadamantane derivatives as therapeutic agents |
| 01/09/2003 | US20030008886 For therapy of pain |
| 01/09/2003 | US20030008881 Substituted phenylcyclohexanecarboxamides and their use |
| 01/09/2003 | US20030008880 4-(2-Pyridyl) piperizines having 5HT7 receptor agonist activity |
| 01/09/2003 | US20030008868 Compounds useful as anti-inflammatory agents |
| 01/09/2003 | US20030008864 Treatment of diseases involving cyst formation |
| 01/09/2003 | US20030008829 For therapy and prophylaxis of inflammatory diseases associated with the respiratory tract, such as asthma and allergic rhinitis, immunomediated inflammatory disorders, such as rheumatoid arthritis, conjunctivitis, psoriasis |
| 01/09/2003 | US20030008293 Detection of polymorphism in preferential nucleotide sequences; obtain cells, extract nucleotide sequences, incubate with probe, detect signal, monitor hybridization pattern |
| 01/09/2003 | US20030008288 Detection and treatment of polycystic kidney disease |
| 01/09/2003 | US20030008022 Medical effect of jojoba oil |
| 01/09/2003 | US20030008021 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 01/09/2003 | US20030007969 Administering integrin antagonist |
| 01/09/2003 | US20030007968 Administering bone marrow cells with lymphyocytes removed; then busulfan |
| 01/09/2003 | US20030007965 Treatment of substance P-related disorders |
| 01/09/2003 | CA2490219A1 Fat-binding polymers |
| 01/09/2003 | CA2452361A1 Use of tyrosine kinase inhibitors for treating autoimmune diseases |
| 01/09/2003 | CA2452200A1 Method for identifying compounds that specifically deplete mast cells |
| 01/09/2003 | CA2451464A1 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 01/09/2003 | CA2451163A1 Agent for preventing or treating organ functional disorders and order dysfunction |
| 01/09/2003 | CA2451128A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 01/09/2003 | CA2451125A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 01/09/2003 | CA2450722A1 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | CA2450686A1 Substituted 8-arylquinoline pde4 inhibitors |
| 01/09/2003 | CA2449486A1 Methods of using soluble epoxide hydrolase inhibitors |
| 01/08/2003 | EP1273580A1 Sulfonyl heteroaryl triazoles as anti-inflammatory and analgesic agents |
| 01/08/2003 | EP1273576A1 Sulfonyl aryl triazoles as anti-inflammatory/analgesic agents |
| 01/08/2003 | EP1272670A2 Diagnosis of diseases associated with dna adducts |
| 01/08/2003 | EP1272615A2 Osteocalcin promoter directed adenovirus replicaton for therapy |
| 01/08/2003 | EP1272514A1 Dna encoding human vanilloid receptor vr3 |
| 01/08/2003 | EP1272511A2 Molecules associated with human reproduction |
| 01/08/2003 | EP1272505A1 8beta-substituted-11beta-pentyl- and 11beta-hexyl-estra-1,3,5(10)-triene derivatives |
| 01/08/2003 | EP1272504A1 8beta-hydrocarbyl-substituted estratrienes for use as selective estrogens |
| 01/08/2003 | EP1272488A2 Tri-aryl-substituted-ethane pde4 inhibitors |
| 01/08/2003 | EP1272487A1 Bicyclic heteroaryl compounds as inhibitors of the interaction between the integrin alpha4beta1 receptor and vcam-1 and/or fibronectin |
| 01/08/2003 | EP1272484A2 Benzoamide piperidine compounds as substance p antagonists |
| 01/08/2003 | EP1272481A1 4-fluoroalkyl-2h-benzopyrans with anti-estrogenic activity |
| 01/08/2003 | EP1272470A1 Amorphous torasemide modification |
| 01/08/2003 | EP1272468A1 Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands |
| 01/08/2003 | EP1272216A2 A vaccine comprising lactobacilli for treating prostate inflammation and benign prostate hyperplasias |
| 01/08/2003 | EP1272204A2 Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof |
| 01/08/2003 | EP1272201A2 Use of compatible solutes as substances having free radical scavenging properties |
| 01/08/2003 | EP1272200A1 Divided dose therapies with vascular damaging activity |
| 01/08/2003 | EP1272185A2 Use of quinazoline derivatives as angiogenesis inhibitors |
| 01/08/2003 | EP1272175A2 Il-8 receptor antagonists |
| 01/08/2003 | EP1272174A1 Combination product comprising a non-steroidal antiandrogen and an egfr tyrosine kinase inhibitor |
| 01/08/2003 | EP1272172A2 Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases |
| 01/08/2003 | EP1272169A2 Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia |
| 01/08/2003 | EP1123276B1 N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them |
| 01/08/2003 | EP1119355B1 Naphthalenecarboxamides as tachykinin receptor antagonists |
| 01/08/2003 | EP0646012B1 WOUND HEALING AND TREATMENT OF FIBROTIC DISORDERS BY TGFbeta-3 |
| 01/08/2003 | CN1390219A Pyrazolopyrimidines as therapeutic agents |
| 01/08/2003 | CN1390194A Stable salts of novel derivatives of 3,3-diphenylpropylamines |
| 01/08/2003 | CN1390142A Taxane prodrugs |
| 01/08/2003 | CN1389248A Diuretic stone-excreting medicine and its prepn. |